The role and regulation of cardiac angiotensin-converting enzyme for noninvasive molecular imaging in heart failure

Current Cardiology Reports

Volumn 9, Issue 2, 2007, Pages 150-158

  Aras, Omer ^b   Messina, Steven A ^b   Shirani, Jamshid ^b   Eckelman, William C ^b   Dilsizian, Vasken ^a  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ; CAPTOPRIL; CARBON 11; CARBOXYPEPTIDASE; CHYMASE; CHYMASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUORINE 18; IODINE 125; KR 31173; LISINOPRIL; N [[4' [(2 ETHYL 5,7 DIMETHYL 3H IMIDAZO[4,5 B]PYRIDIN 3 YL)METHYL] 2 BIPHENYLYL]SULFONYL]BENZAMIDE; NIC 3201; RADIOPHARMACEUTICAL AGENT; RENIN; SK 1080; SMAD PROTEIN; SUNC 8257; TECHNETIUM 99M; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ZOFENOPRILAT;

AUTOCRINE EFFECT; AUTORADIOGRAPHY; BINDING AFFINITY; CELL ACTIVATION; CELL DENSITY; CELL GROWTH; CELL PROLIFERATION; CONGESTIVE HEART FAILURE; DISEASE COURSE; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; ENZYME REGULATION; ENZYME RELEASE; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEART LEFT VENTRICLE CONTRACTILITY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART OUTPUT; HEART TRANSPLANTATION; HEART VENTRICLE REMODELING; HUMAN; ISOTOPE LABELING; MAST CELL; MEDICAL DECISION MAKING; MOLECULAR IMAGING; NON INVASIVE MEASUREMENT; NONHUMAN; PARACRINE SIGNALING; PATHOPHYSIOLOGY; PHARMACOGENETICS; POSITRON EMISSION TOMOGRAPHY; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME; VASOCONSTRICTION;

ANIMALS; DIAGNOSTIC IMAGING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEART FAILURE, CONGESTIVE; HUMANS; LISINOPRIL; MYOCARDIUM; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM; VENTRICULAR DYSFUNCTION, LEFT;

EID: 34247631066     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02938342     Document Type: Review

References (77)

1. Levy D, Kenchaiah S, Larson MG, et al.: Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002, 347:1397-1402.
2. Hunt SA, Baker DW, Chin MH, et al.: ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration with the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. Circulation 2001, 104:2996-3007.
3. Cohn JN, Ferrari R, Sharpe N: Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000, 35:569-582.
4. Harada K, Sugaya T, Murakami K et al.: Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. Circulation 1999, 100:2093-2099.
5. Dilsizian V, Eckelman WC, Loredo ML, et al.: Evidence for tissue angiotensin-converting-enzyme in explanted hearts of ischemic cardiomyopathy using targeted radiotracer technique. J Nucl Med 2007, 48:182-187.
6. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991, 325:293-302.
7. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med 1992, 327:685-691.
8. Riordan JF: Angiotensin-I-converting enzyme and its relatives. Genome Biol 2003, 4:225.
9. Hooper NM, Keen J, Pappin DJ, et al.: Pig kidney angiotensin converting enzyme. Purification and characterization of amphipathic and hydrophilic forms of the enzyme establishes C-terminal anchorage to the plasma membrane. Biochem J 1987, 247:85-93.
10. Paul M, Poyan MA, Kreutz R: Physiology of local renin-angiotensin systems. Physiol Rev 2006, 86:747-803.
11. Dzau VJ, Bernstein K, Celermajer D, et al.: The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol 2001, 88:1L-20L.
12. Dzau VJ: Implications of local angiotensin production in cardiovascular physiology and pharmacology. Am J Cardiol 1987, 59:59A-65A.
13. Bader M: Role of the local renin-angiotensin system in cardiac damage: a minireview focusing on transgenic animal models. J Mol Cell Cardiol 2002, 34:1455-1462.
14. Schunkert H, Dzau VJ, Tang SS, et al.: Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation. J Clin Invest 1990, 86:1913-1920.
15. Passier RC, Smits JF, Verluyten MJ, et al.: Activation of angiotensin-converting enzyme expression in infarct zone following myocardial infarction. Am J Physiol 1995, 269: H1268-H1276.
16. Yamada H, Fabris B, Allen AM, et al.: Localization of angiotensin converting enzyme in rat heart. Circ Res 1991, 68:141-149.
17. Fleming I, Kohlstedt K, Busse R: The tissue renin-angiotensin system and intracellular signalling. Curr Opin Nephrol Hypertens 2006, 15:8-13.
18. Dostal DE, Baker KM: The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? Circ Res 1999, 85:643-650.
19. Baker KM, Aceto JF: Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells. Am J Physiol. 1990, 259:H610-H618.
20. Baker KM, Chernin MI, Wixson SK, et al.: Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Am J Physiol 1990, 259:H324-H332.
21. Sadoshima J, Xu Y, Slayter HS, et al.: Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 1993, 75:977-984.
22. Sun Y, Zhang J, Lu L, et al.: Tissue angiotensin II in the regulation of inflammatory and fibrogenic components of repair in the rat heart. J Lab Clin Med 2004, 143:41-51.
23. Weber KT, Sun Y: Recruitable ACE and tissue repair in the infarcted heart. J Renin Angiotensin Aldosterone Syst 2000, 1:295-303.
24. Zisman LS, Asano K, Dutcher DL, et al.: Differential regulation of cardiac angiotensin converting enzyme binding sites and AT1 receptor density in the failing human heart. Circulation 1998, 98:1735-1741.
25. Zisman LS, Abraham WT, Meixell GE, et al.: Angiotensin II formation in the intact human heart. Predominance of the angiotensin-converting enzyme pathway. J Clin Invest 1995, 96:1490-1498.
26. Urata H, Hoffmann S, Ganten D. Tissue angiotensin II system in the human heart. Eur Heart J 1994, 15(Suppl D):68-78.
27. Miyazaki M, Takai S: Tissue angiotensin II generating system by angiotensin-converting enzyme and chymase. J Pharmacol Sci 2006, 100:391-397.
28. Unger T, Li J: The role of the renin-angiotensin-aldosterone system in heart failure. J Renin Angiotensin Aldosterone Syst 2004, 5(Suppl 1):S7-10.
29. Patella V, Marino I, Arbustini E, et al.: Stem cell factor in mast cells and increased mast cell density in idiopathic and ischemic cardiomyopathy. Circulation 1998, 97:971-978.
30. Sukenaga Y, Kamoshita K, Takai S, et al.: Development of the chymase inhibitor as an anti-tissue-remodeling drug: myocardial infarction and some other possibilities. Jpn J Pharmacol 2002, 90:218-222.
31. Matsumoto T, Wada A, Tsutamoto T, et al.: Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure. Circulation 2003, 107:2555-2558.
32. Kokkonen JO, Lindstedt KA, Kovanen PT: Role for chymase in heart failure: angiotensin II-dependent or -independent mechanisms? Circulation 2003, 107:2522-2524.
33. Mackins CJ, Kano S, Seyedi N, et al.: Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release, and arrhythmias in ischemia/reperfusion. J Clin Invest 2006, 116:1063-1070.
34. Batlle M, Roig E, Perez-Villa F, et al.: Increased expression of the renin-angiotensin system and mast cell density but not of angiotensin-converting enzyme II in late stages of human heart failure. J Heart Lung Transplant 2006, 25:1117-1125.
35. Serneri GG, Boddi M, Cecioni I, et al.: Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function. Circ Res 2001, 88:961-968.
36. Zisman LS, Keller RS, Weaver B, et al.: Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2. Circulation 2003, 108:1707-1712.
37. Der SS, Huentelman MJ, Stewart J, et al.: ACE2: A novel therapeutic target for cardiovascular diseases. Prog Biophys Mol Biol 2006, 91:163-198.
38. Danilczyk U, Eriksson U, Oudit GY, et al.: Physiological roles of angiotensin-converting enzyme 2. Cell Mol Life Sci 2004, 61:2714-2719.
39. Ferrario CM, Trask AJ, Jessup JA: Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol 2005, 289: H2281-H2290.
40. Donoghue M, Hsieh F, Baronas E, et al.: A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000, 87:E1-E9.
41. Crackower MA, Sarao R, Oudit GY, et al.: Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002, 417:822-828.
42. Yamamoto K, Ohishi M, Katsuya T, et al.: Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension 2006, 47:718-726.
43. Tian XL, Pinto YM, Costerousse O, et al.: Over-expression of angiotensin converting enzyme-1 augments cardiac hypertrophy in transgenic rats. Hum Mol Genet 2004, 13:1441-1450.
44. Sun Y, Cleutjens JP, Diaz-Arias AA, et al.: Cardiac angiotensin converting enzyme and myocardial fibrosis in the rat. Cardiovasc Res 1994, 28:1423-1432.
45. Pokharel S, van Geel PP, Sharma UC, et al.: Increased myocardial collagen content in transgenic rats overexpressing cardiac angiotensin-converting enzyme is related to enhanced breakdown of N-acetyl-Ser-Asp-Lys-Pro and increased phosphorylation of Smad2/3. Circulation 2004, 110:3129-3135.
46. Rousseau A, Michaud A, Chauvet MT, et al.: The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme. J Biol Chem 1995, 270:3656-3661.
47. Peng H, Carretero OA, Vuljaj N, et al.: Angiotensin-converting enzyme inhibitors: a new mechanism of action. Circulation 2005, 112:2436-2445.
48. Pradelles P, Frobert Y, Creminon C, et al.: Negative regulator of pluripotent hematopoietic stem cell proliferation in human white blood cells and plasma as analysed by enzyme immunoassay. Biochem Biophys Res Commun 1990, 170:986-993.
49. Zhuo JL, Carretero OA, Peng H, et al.: Characterization of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) receptor binding sites using [125I]-Hpp-Aca-SDKP in rat cardiac fibroblasts. Am J Physiol Heart Circ Physiol 2006, in press.
50. Ikeuchi M, Tsutsui H, Shiomi T, et al.: Inhibition of TGF-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction. Cardiovasc Res 2004, 64:526-535.
51. Tiret L, Rigat B, Visvikis S, et al.: Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 1992, 51:197-205.
52. Danser AH, Derkx FH, Hense HW, et al.: Angiotensinogen (M235T) and angiotensin-converting enzyme (I/D) polymorphisms in association with plasma renin and prorenin levels. J Hypertens 1998, 16:1879-1883.
53. Andersson B, Blange I, Sylven C: Angiotensin-II type I receptor gene polymorphism and long-term survival in patients with idiopathic congestive heart failure. Eur J Heart Fail 1999, 1:363-369.
54. Andersson B, Sylven C: The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure. J Am Coll Cardiol 1996, 28:162-167.
55. Danser AH, Schalekamp MA, Bax WA, et al.: Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation 1995, 92:1387-1388.
56. Davis GK, Millner RW, Roberts DH: Angiotensin converting enzyme (ACE) gene expression in the human left ventricle: effect of ACE gene insertion/deletion polymorphism and left ventricular function. Eur J Heart Fail 2000, 2:253-256.
57. Cicoira M, Zanolla L, Rossi A, et al.: Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. J Am Coll Cardiol 2001, 37:1808-1812.
58. McNamara DM, Holubkov R, Postava L, et al.: Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J Am Coll Cardiol 2004, 44:2019-2026.
59. Candy GP, Skudicky D, Mueller UK, et al.: Association of left ventricular systolic performance and cavity size with angiotensin-converting enzyme genotype in idiopathic dilated cardiomyopathy. Am J Cardiol 1999, 83:740-744.
60. Dellgren G, Eriksson MJ, Blange I, et al.: Angiotensin-converting enzyme gene polymorphism influences degree of left ventricular hypertrophy and its regression in patients undergoing operation for aortic stenosis. Am J Cardiol 1999, 84:909-913.
61. Schunkert H, Hense HW, Holmer SIR, et al.: Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. N Engl J Med 1994, 330:1634-1638.
62. Lindpaintner K, Lee M, Larson MG, et al.: Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular mass. N Engl J Med 1996, 334:1023-1028.
63. Fyhrquist F, Tikkanen I, Gronhagen-Riska C, et al.: Inhibitor binding assay for angiotensin-converting enzyme. Clin Chem 1984, 30:696-700.
64. Shirani J, Loredo ML, Eckelman WC, et al.: Imaging the renin-angiotensin-aldosterone system in the heart. Curr Heart Fail Rep 2005, 2:78-86.
65. Matarrese M, Salimbeni A, Turolla EA, et al.: 11C-Radiosynthesis and preliminary human evaluation of the disposition of the ACE inhibitor [11C]zofenoprilat. Bioorg Med Chem 2004, 12:603-611.
66. Lee YHC, Kiesewetter DO, Lang L, et al.: Synthesis of 4-[18F] fluorobenzoyllisinopril: a radioligand for angiotensin converting enzyme (ACE) imaging with positron emission tomography. J Labelled Comp Radiopharm 2001, 44: S268-S270.
67. Fernia FJ, Maresca KP, Joyal JL, et al.: Synthesis and evaluation of radioligands for angiotensin converting enzyme (ACE) imaging. J Nucl Med 2006, 5:260P.
68. Johnston CI, Fabris B, Yamada H, et al.: Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. J Hypertens Suppl 1989, 7:S11-S16.
69. Schunkert H, Jackson B, Tang SS, et al.: Distribution and functional significance of cardiac angiotensin converting enzyme in hypertrophied rat hearts. Circulation 1993, 87:1328-1339.
70. Kohzuki M, Kanazawa M, Yoshida K, et al.: Cardiac angiotensin converting enzyme and endothelin receptor in rats with chronic myocardial infarction. Jpn Circ J 1996, 60:972-980.
71. Schuster DP, McCarthy TJ, Welch MJ, et al.: In vivo measurements of pulmonary angiotensin-converting enzyme kinetics. II. Implementation and application. J Appl Physiol 1995, 78:1169-1178.
72. Moskowitz DW: From pharmacogenomics to improved patient outcomes: angiotensin I-converting enzyme as an example. Diabetes Technol Ther 2002, 4:519-532.
73. Mathews WB, Burns HD, Dannals RF: Carbon-11 labeling of the potent nonpeptide angiotensin-II antagonist MK-996. J Labelled Comp Radiopharm 1995, 36:729-737.
74. Hamill TG, Burns HD, Dannals RF, et al.: Development of [11C]L-159,884: a radiolabelled, nonpeptide angiotensin II antagonist that is useful for angiotensin II, AT1 receptor imaging. Appl Radiat Isot 1996, 47:211-218.
75. Szabo Z, Speth RC, Brown PR, et al.: Use of positron emission tomography to study AT1 receptor regulation in vivo. J Am Soc Nephrol 2001, 12:1350-1358.
76. Lee SH, Jung YS, Lee BH, et al.: Characterization of angiotensin II antagonism displayed by SK-1080, a novel nonpeptide AT1-rcceptor antagonist. J Cardiovasc Pharmacol 1999, 33:367-374.
77. Verjans J, Lovhaug D, Narula N: Noninvasive imaging of myocardial angiotensin receptors in heart failure. 25th Annual Scientific Sessions of Western States Affiliates of American Heart Association. Irvine, CA: September 30, 2005.